Since 2016, Evotec is applying its operational venturing model, which started with the creation of Evotec’s first spin-off Topas Therapeutics. Since then, Evotec’s equity investment portfolio has grown steadily. We have more than 20 investments with more than 90 active projects in our EVOequity pipeline.
Our investment focus spans predominantly early-stage biotechnology companies that benefit from an experienced drug discovery partner at both operational and strategic level and where operational synergies provide a strong additional value-add for both parties.
By providing access to Evotec’s industrialised and integrated technology platforms and expertise, Evotec facilitates acceleration of early-stage scientific projects and supports product development up to IND-readiness and beyond.
We are committed to stay a true long-term partner to start-ups. We provide technology expertise and capital, and we use the possibilities of sharing Evotec’s international investor and partner network.
We invest predominantly in early-stage biotechnology companies that have strong operational synergies with Evotec’s in-house areas of expertise. We focus on multi-modalities, including biologics, small molecules (extension to difficult targets), gene therapy, iPSCs and scalable cell therapy. We have a strong interest in patient-data-based discovery projects.
Evotec takes both minority as well as majority stakes, between 1-50%.
We draw our investments from our broad biotech customer base, realise investments from a growing number of academic partnerships through BRIDGEs, and access deal-flow from expanding external networks in Europe and US. In addition, Evotec accelerates innovation via risk-shared venture creation through spinning out new companies based on in-house platforms.
To date, Evotec has invested in early-stage life sciences companies with more than € 90 m and this is expected to accelerate in the upcoming years. EVOequity has the potential to become an important pillar of Evotec’s long-term value generation.
